Watson and Amgen to collaborate on biosimilar anti-cancer drugs By Dr Ananya Mandal.
Watson and Amgen to collaborate on biosimilar anti-cancer drugs By Dr Ananya Mandal, MD Amgen, the biggest standalone biotechnology company, and generic drug firm Watson Pharmaceuticals will collaborate on developing biosimilar medicines for cancer. The idea, basically, is that the projects are as well high-risk and expensive for just one company, and that Amgen will contribute manufacturing experience while Watson will deliver advertising knowledge. The pact, nevertheless, doesn’t keep Watson from pursuing advancement of biosimilar versions of Amgen products, which include biologics with an increase of than $1 billion in annual revenue such as Enbrel, Aranesp and Epogen http://sildalis.org .
Amgen can continue to collect security and efficacy data in this long-term exposure period. A PASI score is a measure of psoriatic plaque redness, scaling and thickness and the level of involvement in each area of the physical body. Treatment efficacy is often measured by the reduced amount of PASI from baseline . SPGA is usually a physician’s rating of psoriasis severity at a given point in time based on plaque, redness and scaling. A physician can rate a patient’s psoriasis as obvious , almost clear , mild , moderate , severe , or very serious . About Psoriasis Psoriasis is a serious, chronic inflammatory disease that triggers raised, red, scaly patches to appear on the skin, typically affecting the outside of the elbows, knees or scalp, though it could appear on any area.